Pharmanovia, a global pharmaceutical company that commercializes new medicines and revitalizes, extends and extends the cycle of established medicines, today announced the expansion of its endocrinology portfolio with a new licensing agreement for GHRYVELIN™ (macimorelin), a new medication applied to diagnose Growth Hormone Deficiency (GHD) in adults from Aeterna Zentaris.

The release in the original language is the official and authorized version thereof. This translation is only a means of help and must be compared with the text in the original language, which is the only version of the text that will have legal validity.

Contacts
For more information:
Alison Dyson, Pharmanovia Communications Director
07-442-256-310/ alison.dyson@pharmanovia.com
or pharmanovia@67health.co.uk